---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-005038"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:29:04.442730+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fulcrum doses first patient in Phase 1b of FTX-6058; cash $218.2M; appoints Kate Haviland as Chair

## Summary
- Cash, cash equivalents, and marketable securities of $218.2M as of Dec 31, 2021 (unaudited), sufficient into 2024.
- First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; initial data expected Q2 2022.
- IND submitted for FTX-6058 to start Phase 1b in select hemoglobinopathies (beta-thalassemia) in Q2 2022.
- Update on losmapimod Phase 3 plan for FSHD expected in Q1 2022; no new data yet.
- Kate Haviland appointed Chair of board; Mark Levin resigns effective April 18, 2022 (no disagreement).

## SEC filing metadata
- accession: 0001193125-22-005038
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/0001193125-22-005038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/d157429d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-005038
- JSON: https://secwatch.observer/filing/0001193125-22-005038.json
- Plain text: https://secwatch.observer/filing/0001193125-22-005038.txt

## Key facts
- Executive change
  Kate Haviland was named as Chair at Fulcrum Therapeutics, Inc..
  - Action: named
  - Role: Chair
  source text: On January 10, 2022, the Company announced that Kate Haviland has been named Chair of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/0001193125-22-005038-index.htm
- Executive change
  Mark Levin resigned as Executive Chairman at Fulcrum Therapeutics, Inc..
  - Action: resigned
  - Role: Executive Chairman
  source text: On January 5, 2022, Mark Levin notified the Company of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective April 18, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/0001193125-22-005038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.